AstraZeneca resumes clinical trials for its Covid-19 vaccine candidate

AstraZeneca resumes clinical trials for its Covid-19 vaccine candidate

PanARMENIAN.Net - AstraZeneca on Monday, September 14 resumed clinical trials for its Covid-19 vaccine candidate, Reuters reports.

The resumption of the trials for AstraZeneca’s vaccine, one of the most advanced in development and regarded by governments and financial markets as one of the best bets to tackle the health crisis in the months ahead, buoyed stock markets around the world.

Late-stage trials of the vaccine were suspended last week after an illness in a study participant, casting doubts on an early rollout and sending the London-listed company’s shares lower.

Global trials of the vaccine had also been paused following the UK suspension. Brazil has approved restarting the trials and the Serum Institute of India is awaiting permission from the Drugs Controller General of India.

Cambridge-based AstraZeneca’s shares had risen about 11% this year up to their Friday close of 8,429 pence, giving the pharmaceutical giant a market capitalisation of 111 billion pounds ($142 billion).

 Top stories
Authorities said a total of 192 Azerbaijani troops were killed and 511 were wounded during Azerbaijan’s offensive.
In 2023, the Azerbaijani government will increase the country’s defense budget by more than 1.1 billion manats ($650 million).
The bill, published on Monday, is designed to "eliminate the shortcomings of an unreasonably broad interpretation of the key concept of "compatriot".
The earthquake caused a temporary blackout, damaged many buildings and closed a number of rural roads.
Partner news
---